C4X Discovery Holdings PLC C4XD presents data on Orexin-1 antagonist
13 November 2017 - 6:00PM
RNS Non-Regulatory
TIDMC4XD
C4X Discovery Holdings PLC
13 November 2017
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
C4XD presents data on its lead addiction programme: Orexin-1
antagonist
Programme demonstrates potential application across a broad
range of substance use disorders
13 November 2017 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering drug discovery company, presented new pre-clinical data
on its Orexin-1 antagonist programme at Neuroscience 2017 on 11(th)
November 2017 in Washington, DC.
C4XD's lead programme, Orexin-1, aims to treat addiction by
targeting the "craving" process itself and, therefore, can be
applied across a broad range of substance use disorders. Of
particular note, C4XD announced new efficacy data of its lead
compound, C4X_3256, in in vivo models of nicotine
self-administration and cue-induced reinstatement. This supports
the development of this compound as a therapy across two distinct
areas of nicotine abuse; smoking cessation and relapse in
smokers.
Clive Dix, Chief Executive Officer of C4XD, said: "This set of
studies strengthens C4XD's pre-clinical data package for our lead
Orexin-1 antagonist programme. We strongly believe that the
programme presents a compelling commercial case for partnership due
to its broad applicability to substance use as well as related
disorders, such as anxiety, post-traumatic stress disorder, and
impulse control. This is supported by the high level of
pre-clinical partnering interest received that have enabled us to
enter late-stage commercial discussions."
Data presentation details:
Title: Efficacy of a novel selective oral Orexin 1 receptor
antagonist in rat models of nicotine self-administration and
reinstatement
Authors: C. Murray, G. A. Higgins, B. P. Martin, T. Nowak, J. C.
Fox;
C4X Discovery, Manchester, United Kingdom; Intervivo Solutions
Inc, Toronto, ON, Canada
To view the full abstract, please follow this link.
--ENDS-
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Panmure Gordon (UK) Limited (NOMAD and Broker) 020 7886 2500
Freddy Crossley, Duncan Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Matthew Neal, Melissa Gardiner 0203 709
5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4XD's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline in addiction,
diabetes and inflammation with a number of new drug candidates
identified and further progress made towards the clinic. In
selecting new targets C4X Discovery will focus on the high-value
disease areas of inflammation and neurodegeneration, and will
continue to maximise value from opportunistic areas, for example,
immuno-oncology, addiction, and diabetes.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4XD to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALFFIVLVLFLID
(END) Dow Jones Newswires
November 13, 2017 02:00 ET (07:00 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024